Kane Biotech Schedules Full Year 2018 Earnings Conference Call and Business Update
March 20 2019 - 4:30PM
Kane Biotech Inc. (TSX-V:KNE), (the “Corporation” or “Kane
Biotech”), is pleased to announce today that it will host a
conference call and webcast on Tuesday, March 26, 2019 at 4:00pm
Eastern Time to discuss its financial results for the fourth
quarter and full year 2018, in conjunction with the filing of its
annual Year End Financial Statements for the fourth quarter and
full year ended December 31, 2018.
Marc Edwards, Chief Executive Officer and Ray Dupuis, Chief
Financial Officer of Kane Biotech, will host the call and provide
an update on the Company’s business strategy including product
developments, licensing and business development and other
initiatives in progress. There will be an opportunity for
participants dialed-in via conference call to ask questions to
management in a Q&A session taking place following his prepared
remarks. To participate in the call, please dial 1-877-268-9044
(toll-free) in the U.S. and Canada. The conference ID number for
both the call and webcast is 6958649.
Event: |
Kane
Biotech Investor Update |
Date: |
Tuesday, March 26, 2019 |
Time: |
4:00pm (Eastern Time) |
Participant Dial-in: |
1-877-268-9044 (toll free) |
Conference ID: |
6958649 |
Webcast Link: |
https://edge.media-server.com/m6/p/yfay2q7s |
A live and archived audio webcast of the conference call will
also be available on the investor relations page of Kane Biotech’s
corporate website at www.kanebiotech.com.
About Kane Biotech Kane Biotech is a
biotechnology company engaged in the research, development and
commercialization of technologies and products that prevent and
remove microbial biofilms. The Corporation has a portfolio of
biotechnologies, intellectual property (66 patents and patents
pending, trade secrets and trademarks) and products developed by
the Corporation’s own biofilm research expertise and acquired from
leading research institutions. StrixNB(TM), DispersinB(R),
Aledex(R), bluestem(TM), AloSera(TM), coactiv+(TM) and
Kane(R) are trademarks of Kane Biotech Inc. The Corporation is
listed on the TSX Venture Exchange under the symbol "KNE".
For more information,
please visit www.kanebiotech.com or contact: |
|
Marc Edwards |
|
Chief Executive
Officer |
|
Kane Biotech Inc. |
|
+1 (514) 910-6991 |
medwards@kanebiotech.com |
|
|
Grant Humphrey |
|
Vice President, Sales
and Business Development |
|
Kane Biotech Inc. |
|
+1 (204) 914-5089 |
ghumphrey@kanebiotech.com |
|
|
Joe Green |
|
US. Investor
Relations |
|
Edison Inc. |
|
+1 (646) 653-7030 |
jgreen@edisongroup.com |
Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of
this release.
Caution Regarding Forward-Looking Information
This press release contains certain statements regarding Kane
Biotech Inc. that constitute forward-looking information under
applicable securities law. These statements reflect management’s
current beliefs and are based on information currently available to
management. Certain material factors or assumptions are applied in
making forward-looking statements, and actual results may differ
materially from those expressed or implied in such statements.
These risks and uncertainties include, but are not limited to,
risks relating to the Company’s: (a) financial condition, including
lack of significant revenues to date and reliance on equity and
other financing; (b) business, including its early stage of
development, government regulation, market acceptance for its
products, rapid technological change and dependence on key
personnel; (c) intellectual property including the ability of the
Company to protect its intellectual property and dependence on its
strategic partners; and (d) capital structure, including its lack
of dividends on its common shares, volatility of the market price
of its common shares and public company costs. Further information
about these and other risks and uncertainties can be found in the
disclosure documents filed by the Company with applicable
securities regulatory authorities, available at www.sedar.com. The
Company cautions that the foregoing list of factors that may affect
future results is not exhaustive.
Kane Biotech (TSXV:KNE)
Historical Stock Chart
From Aug 2024 to Sep 2024
Kane Biotech (TSXV:KNE)
Historical Stock Chart
From Sep 2023 to Sep 2024